Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Holdings Trimmed by Fmr LLC

FMR LLC trimmed its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 67.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,724,015 shares of the company's stock after selling 3,605,931 shares during the quarter. FMR LLC owned 2.76% of Fulcrum Therapeutics worth $6,155,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP raised its position in Fulcrum Therapeutics by 13.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,480,926 shares of the company's stock valued at $9,182,000 after purchasing an additional 176,114 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Fulcrum Therapeutics by 223.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company's stock valued at $2,032,000 after buying an additional 393,202 shares during the period. Assenagon Asset Management S.A. purchased a new position in Fulcrum Therapeutics in the 2nd quarter worth approximately $3,084,000. Marshall Wace LLP grew its position in Fulcrum Therapeutics by 47.7% in the second quarter. Marshall Wace LLP now owns 333,161 shares of the company's stock valued at $2,066,000 after acquiring an additional 107,588 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Fulcrum Therapeutics during the second quarter valued at approximately $1,158,000. 89.83% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on FULC shares. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Thursday, September 12th. HC Wainwright restated a "neutral" rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. Bank of America downgraded Fulcrum Therapeutics from a "neutral" rating to an "underperform" rating and dropped their price objective for the stock from $10.00 to $2.00 in a report on Thursday, September 12th. Leerink Partnrs cut Fulcrum Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, September 12th. Finally, Royal Bank of Canada reissued a "sector perform" rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Fulcrum Therapeutics currently has an average rating of "Hold" and a consensus target price of $9.33.

Fulcrum Therapeutics Stock Down 1.5 %

FULC stock traded down $0.06 during mid-day trading on Friday, reaching $3.97. The company had a trading volume of 411,131 shares, compared to its average volume of 980,094. Fulcrum Therapeutics, Inc. has a one year low of $2.86 and a one year high of $13.70. The stock has a market capitalization of $214.14 million, a P/E ratio of -12.90 and a beta of 2.14. The stock's 50-day simple moving average is $3.50 and its two-hundred day simple moving average is $5.96.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.